Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
- PMID: 37799725
- PMCID: PMC10547882
- DOI: 10.3389/fimmu.2023.1251645
Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis
Abstract
Immune checkpoint inhibitors (ICIs) modulate the body's immune function to treat tumors but may also induce pneumonitis. Immune checkpoint inhibitor-related pneumonitis (ICIP) is a serious immune-related adverse event (irAE). Immunotherapy is currently approved as a first-line treatment for non-small cell lung cancer (NSCLC), and the incidence of ICIP in NSCLC patients can be as high as 5%-19% in clinical practice. ICIP can be severe enough to lead to the death of NSCLC patients, but there is a lack of a gold standard for the diagnosis of ICIP. Radiomics is a method that uses computational techniques to analyze medical images (e.g., CT, MRI, PET) and extract important features from them, which can be used to solve classification and regression problems in the clinic. Radiomics has been applied to predict and identify ICIP in NSCLC patients in the hope of transforming clinical qualitative problems into quantitative ones, thus improving the diagnosis and treatment of ICIP. In this review, we summarize the pathogenesis of ICIP and the process of radiomics feature extraction, review the clinical application of radiomics in ICIP of NSCLC patients, and discuss its future application prospects.
Keywords: deep learning; immune checkpoint inhibitor-related pneumonitis; immunotherapy; non-small cell lung cancer; radiomics.
Copyright © 2023 Shu, Xu, Su, Ran, Liu, Zhang, Zhao, Chao and Fu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Image classification of immune checkpoint inhibitor-related pneumonia in lung cancer patients.Clin Imaging. 2022 Jun;86:31-37. doi: 10.1016/j.clinimag.2022.03.012. Epub 2022 Mar 18. Clin Imaging. 2022. PMID: 35325631
-
Radiomics Biomarkers to Predict Checkpoint Inhibitor Pneumonitis in Non-small Cell Lung Cancer.Acad Radiol. 2025 Mar;32(3):1685-1695. doi: 10.1016/j.acra.2024.09.053. Epub 2024 Oct 11. Acad Radiol. 2025. PMID: 39395887
-
Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer.Front Immunol. 2022 Apr 26;13:870842. doi: 10.3389/fimmu.2022.870842. eCollection 2022. Front Immunol. 2022. PMID: 35558076 Free PMC article.
-
The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.Int Immunopharmacol. 2021 Oct;99:108011. doi: 10.1016/j.intimp.2021.108011. Epub 2021 Aug 10. Int Immunopharmacol. 2021. PMID: 34426108
-
Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.Clin Lung Cancer. 2020 Sep;21(5):e435-e444. doi: 10.1016/j.cllc.2020.02.025. Epub 2020 Mar 9. Clin Lung Cancer. 2020. PMID: 32576443 Review.
Cited by
-
Automatic machine learning accurately predicts the efficacy of immunotherapy for patients with inoperable advanced non-small cell lung cancer using a computed tomography-based radiomics model.Diagn Interv Radiol. 2025 Mar 3;31(2):130-140. doi: 10.4274/dir.2024.242972. Epub 2025 Jan 16. Diagn Interv Radiol. 2025. PMID: 39817633 Free PMC article.
-
Radiomics Models to Predict Tumor Response and Pneumonitis in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.J Clin Med. 2025 Jun 18;14(12):4330. doi: 10.3390/jcm14124330. J Clin Med. 2025. PMID: 40566074 Free PMC article.
-
A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence.Front Immunol. 2024 Nov 28;15:1496627. doi: 10.3389/fimmu.2024.1496627. eCollection 2024. Front Immunol. 2024. PMID: 39669560 Free PMC article. Review.
-
Biomarkers and ImmuneScores in lung cancer: predictive insights for immunotherapy and combination treatment strategies.Biol Proced Online. 2025 Jul 10;27(1):25. doi: 10.1186/s12575-025-00287-0. Biol Proced Online. 2025. PMID: 40640703 Free PMC article. Review.
References
-
- Siddiqui F, Vaqar S, Siddiqui AH. Lung Cancer. Treasure Island (FL): StatPearls Publishing; (2022) 2022. - PubMed
-
- Azzouqa AG, Chen RQ, Lou YY, Ailawadhi S, Manochakian R. Impact of time to treatment initiation (Tti) on survival of patients with newly diagnosed non-small cell lung cancer (Nsclc). J Clin Oncol (2019) 37(15):9058. doi: 10.1200/JCO.2019.37.15_suppl.9058 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical